Zobrazeno 1 - 10
of 90
pro vyhledávání: '"FG Haluska"'
Publikováno v:
Blood. 84:1005-1019
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c353558defd764c75cd912f35e07423
https://doi.org/10.1182/blood.v84.4.1005.1005
https://doi.org/10.1182/blood.v84.4.1005.1005
Autor:
George S; Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., von Mehren M; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Fletcher JA; Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Sun J; Clinical Research, ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Zhang S; Clinical Research, ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Pritchard JR; Clinical Research, ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Hodgson JG; Clinical Research, ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Kerstein D; Oncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Rivera VM; Clinical Research, ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Haluska FG; Clinical Research, ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Heinrich MC; Medical Oncology, Portland VA Health Care System and Oregon Health & Sciences University Knight Cancer Institute, Portland, Oregon.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 01; Vol. 28 (7), pp. 1268-1276.
Autor:
Cortes JE; The University of Texas MD Anderson Cancer Center, Houston, TX., Kim DW; Seoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea., Pinilla-Ibarz J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL., le Coutre PD; Charité, Universitätsmedizin Berlin, Berlin, Germany., Paquette R; Cedars-Sinai Medical Center, Los Angeles, CA., Chuah C; Singapore General Hospital, Duke-National University of Singapore (NUS) Medical School, Singapore., Nicolini FE; Centre Hospitalier Lyon-Sud, Pierre-Bénite, Lyon, France., Apperley JF; Centre for Haematology, Imperial College, London, United Kingdom., Khoury HJ; Winship Cancer Institute of Emory University, Atlanta, GA., Talpaz M; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA., Abruzzese E; S. Eugenio Hospital, Tor Vergata University, Rome, Italy., Rea D; Service d'Hématologie Adulte et Centre d'Investigation Clinique, Hôpital Saint Louis, Paris, France., Baccarani M; Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy., Müller MC; III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany., Gambacorti-Passerini C; University of Milano-Bicocca/San Gerardo Hospital, Monza, Italy., Lustgarten S; ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Rivera VM; ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Haluska FG; ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Guilhot F; Centre d'Investigation Clinique (CIC) 1402, INSERM, Poitiers, France.; Centre Hospitalier Universitaire de Poitiers, Poitiers, France., Deininger MW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Hochhaus A; Hematology/Oncology, Jena University Hospital, Jena, Germany., Hughes TP; University of Adelaide/South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia; and., Shah NP; Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
Blood [Blood] 2018 Jul 26; Vol. 132 (4), pp. 393-404. Date of Electronic Publication: 2018 Mar 22.
Autor:
Kim DW; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Tiseo M; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Ahn MJ; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Reckamp KL; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Hansen KH; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Kim SW; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Huber RM; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., West HL; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Groen HJM; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Hochmair MJ; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Leighl NB; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Gettinger SN; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Langer CJ; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Paz-Ares Rodríguez LG; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Smit EF; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Kim ES; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Reichmann W; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Haluska FG; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Kerstein D; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO., Camidge DR; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Aug 01; Vol. 35 (22), pp. 2490-2498. Date of Electronic Publication: 2017 May 05.
Autor:
Pearson AD; Paediatric Drug Development Unit, Children and Young People's Unit, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom., Federico SM; Department of Pediatric Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA., Aerts I; Department of Pediatric, Adolescent and Young Adult Oncology, Institut Curie, Paris, France., Hargrave DR; Haematology and Oncology Department, Great Ormond Street Hospital for Children, London, United Kingdom., DuBois SG; Department of Pediatrics, University of California San Francisco School of Medicine, and Benioff Children's Hospital, San Francisco, CA, USA.; Current affiliation: Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA., Iannone R; Clinical Research, Merck & Co., Inc., North Wales, PA, USA., Geschwindt RD; Clinical Research, Merck & Co., Inc., North Wales, PA, USA., Wang R; BARDS, MSD R&D (China) Co. Ltd., Beijing, China., Haluska FG; Clinical Research & Development, ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA., Trippett TM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Geoerger B; Department of Childhood and Adolescent Oncology, Gustave Roussy, University Paris-Sud, Villejuif, France.
Publikováno v:
Oncotarget [Oncotarget] 2016 Dec 20; Vol. 7 (51), pp. 84736-84747.
Autor:
Gettinger SN; Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA. Electronic address: scott.gettinger@yale.edu., Bazhenova LA; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA., Langer CJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Salgia R; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA., Gold KA; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA., Rosell R; Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain., Shaw AT; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Weiss GJ; Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, AZ, USA., Tugnait M; ARIAD Pharmaceuticals, Cambridge, MA, USA., Narasimhan NI; ARIAD Pharmaceuticals, Cambridge, MA, USA., Dorer DJ; ARIAD Pharmaceuticals, Cambridge, MA, USA., Kerstein D; ARIAD Pharmaceuticals, Cambridge, MA, USA., Rivera VM; ARIAD Pharmaceuticals, Cambridge, MA, USA., Clackson T; ARIAD Pharmaceuticals, Cambridge, MA, USA., Haluska FG; ARIAD Pharmaceuticals, Cambridge, MA, USA., Camidge DR; University of Colorado Cancer Center, Aurora, CO, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2016 Dec; Vol. 17 (12), pp. 1683-1696. Date of Electronic Publication: 2016 Nov 08.
Autor:
Dorer DJ; ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234, USA. Electronic address: david.dorer@ariad.com., Knickerbocker RK; ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234, USA. Electronic address: ronald.knickerbocker@ariad.com., Baccarani M; Department of Hematology and Oncology, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. Electronic address: michele.baccarani@unibo.it., Cortes JE; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, 77030, Houston, TX, USA. Electronic address: jcortes@mdanderson.org., Hochhaus A; Department of Hematology and Medical Oncology, Jena University Hospital, Erlanger Allee 101, 07747, Jena, Germany. Electronic address: andreas.hochhaus@med.uni-jena.de., Talpaz M; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Room 4302, Ann Arbor, MI, 48109-5936, USA. Electronic address: mtalpaz@med.umich.edu., Haluska FG; ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234, USA. Electronic address: frank.haluska@ariad.com.
Publikováno v:
Leukemia research [Leuk Res] 2016 Sep; Vol. 48, pp. 84-91. Date of Electronic Publication: 2016 Jul 22.
Autor:
Lipton JH; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: Jeff.Lipton@uhn.ca., Chuah C; Duke-NUS Medical School, Singapore General Hospital, Singapore., Guerci-Bresler A; Brabois Hospital, Vandoeuvre-lès-Nancy, France., Rosti G; Institute of Hematology, University of Bologna, Bologna, Italy., Simpson D; North Shore Hospital, Westlake, Auckland, New Zealand., Assouline S; Department of Oncology, Jewish General Hospital, McGill University, Montréal, QC, Canada., Etienne G; Département d'Hématologie, Institut Bergonié, Bordeaux, France., Nicolini FE; Haematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, France., le Coutre P; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Clark RE; Department of Haematology, Royal Liverpool University Hospital, Liverpool, Merseyside, UK., Stenke L; Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden., Andorsky D; Rocky Mountain Cancer Centers, Boulder, CO, USA., Oehler V; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Lustgarten S; ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA., Rivera VM; ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA., Clackson T; ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA., Haluska FG; ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA., Baccarani M; Department of Hematology and Oncology, University of Bologna, Bologna, Italy., Cortes JE; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guilhot F; INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, Poitiers, France., Hochhaus A; Abteilung für Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany., Hughes T; Haematology Division, Royal Adelaide Hospital, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah NP; Department of Medicine (Hematology/Oncology), University of California, San Francisco, San Francisco, CA, USA., Talpaz M; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA., Deininger MW; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2016 May; Vol. 17 (5), pp. 612-21. Date of Electronic Publication: 2016 Apr 12.
Autor:
Deininger MW; Huntsman Cancer Institute University of Utah, Salt Lake City, UT;, Hodgson JG; ARIAD Pharmaceuticals, Inc., Cambridge, MA;, Shah NP; University of California San Francisco, San Francisco, CA;, Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;, Kim DW; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea;, Nicolini FE; Centre Hospitalier Lyon Sud, Pierre Benite, & INSERM U1052, Lyon, France;, Talpaz M; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI;, Baccarani M; Department of Hematology-Oncology 'L. and A. Seragnoli,' S. Orsola-Malpighi University Hospital, Bologna, Italy;, Müller MC; III. Med. Klinik, Universitätsmedizin Mannheim, Mannheim, Germany;, Li J; MolecularMD, Portland, OR;, Parker WT; Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and., Lustgarten S; ARIAD Pharmaceuticals, Inc., Cambridge, MA;, Clackson T; ARIAD Pharmaceuticals, Inc., Cambridge, MA;, Haluska FG; ARIAD Pharmaceuticals, Inc., Cambridge, MA;, Guilhot F; INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, France;, Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;, Soverini S; Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy;, Hochhaus A; Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany;, Hughes TP; SA Pathology and South Australian Health and Medical Research Institute, Adelaide, Australia; Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and., Rivera VM; ARIAD Pharmaceuticals, Inc., Cambridge, MA;, Branford S; Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.
Publikováno v:
Blood [Blood] 2016 Feb 11; Vol. 127 (6), pp. 703-12. Date of Electronic Publication: 2015 Nov 24.
Autor:
Oza AM; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA. amit.oza@uhn.ca., Pignata S; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Poveda A; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., McCormack M; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Clamp A; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Schwartz B; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Cheng J; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Li X; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Campbell K; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Dodion P; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA., Haluska FG; Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori 'Fondazione G Pascale'-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Nov 01; Vol. 33 (31), pp. 3576-82. Date of Electronic Publication: 2015 Jun 15.